KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

West Pharmaceutical Services (WST) Leases (2016 - 2025)

West Pharmaceutical Services' Leases history spans 13 years, with the latest figure at $117.0 million for Q4 2025.

  • For Q4 2025, Leases rose 11.96% year-over-year to $117.0 million; the TTM value through Dec 2025 reached $117.0 million, up 11.96%, while the annual FY2025 figure was $117.0 million, 11.96% up from the prior year.
  • Leases for Q4 2025 was $117.0 million at West Pharmaceutical Services, up from $35.2 million in the prior quarter.
  • Across five years, Leases topped out at $117.0 million in Q4 2025 and bottomed at $31.0 million in Q2 2024.
  • The 5-year median for Leases is $91.7 million (2022), against an average of $81.3 million.
  • The largest annual shift saw Leases skyrocketed 50.65% in 2022 before it plummeted 68.75% in 2024.
  • A 5-year view of Leases shows it stood at $69.3 million in 2021, then skyrocketed by 50.65% to $104.4 million in 2022, then dropped by 4.98% to $99.2 million in 2023, then increased by 5.34% to $104.5 million in 2024, then rose by 11.96% to $117.0 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Leases are $117.0 million (Q4 2025), $35.2 million (Q3 2025), and $35.0 million (Q2 2025).